News

Solvonis Therapeutics (LSE:SVNS) CEO Anthony Tennyson joined Proactive's Stephen Gunnion to discuss positive bridging pharmacokinetic data from the SVN-002 programme and what it means for the company's strategy in alcohol use disorder. Solvonis is advancing SVN-002 toward a Phase 2b trial for moderate to severe alcohol use disorder in the US, repurposing Johnson & Johnson's approved esketamine treatment Spravato via the FDA's 505(b)(2) pathway. Preclinical PK studies showed comparable exposure levels of esketamine and its metabolites via sublingual and buccal delivery compared with intranasal administration — a key step in establishing the scientific bridge the FDA requires. "We've established that esketamine delivered sublingual and buccal delivers the same exposure as esketamine delivered intranasal," Tennyson said. He pointed to a substantial commercial opportunity, with alcohol use disorder affecting around 15 million American adults, a far larger market than the treatment-resistant depression population Spravato currently serves. Tennyson said the data could support a narrower toxicology package and a faster, capital-efficient development timeline. Next steps include FDA discussions on toxicology requirements ahead of an IND application for the planned Phase 2b trial. For more Proactive interviews and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #SolvonisTherapeutics #AnthonyTennyson #SVN002 #AlcoholUseDisorder #AUD #Biotech #Pharma #DrugDevelopment #Esketamine #Spravato #ClinicalTrials #FDA #HealthcareInnovation #LifeSciences #Investing

This research roundup highlights a mix of opportunities and risks across large-cap technology, healthcare, and micro-cap stocks.

Johnson & Johnson (NYSE:JNJ) is one of Kevin O’Leary’s top stock picks for 2026 through the O’Shares U.S. Quality Dividend ETF. The stock made up 5.33% of the ETF as of June 17, 2026. On June 15, 2026, Johnson & Johnson announced an investment of more than $1 billion in Jacksonville, Florida, to expand its […]

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week. Earned income depends on showing up. Dividend income depends on a board of directors ... Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income

Our Johnson & Johnson (NYSE:JNJ) 24/7 Wall St. price target lands at $261.72, pointing to 11.28% upside from the current price of $235.18. Our recommendation is buy, and our model carries a 90% confidence level. JNJ has quietly become one of healthcare’s most reliable compounders again, with oncology firing and dividend support intact. Metric Value ... Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside

Generating a six-figure income from a $500,000 portfolio through yield alone is largely unrealistic. Doing so would require a payout approaching 20%, a level that few investments can sustain for long. The more practical approach is to combine a reasonable starting yield with businesses that consistently increase their dividends. Over time, dividend growth and compounding ... The Dividend Growth Path That Turns $500,000 Into a Six-Figure Income Stream

The average retired worker receives about $24,000 a year from Social Security. Add a modest part-time job, the kind many retirees take for supplemental income rather than career advancement, and total annual income often lands somewhere between $40,000 and $45,000 before taxes. For millions of retirees, that combination defines the retirement budget. A portfolio can ... This Dividend Portfolio Pays More Than Social Security and a Part-Time Job Combined

A $2 million dividend portfolio may appear straightforward on paper, but the amount investors actually get to spend depends heavily on taxes. In California, the gap between gross portfolio income and after-tax cash flow can be substantial. Federal dividend tax rates, the net investment income tax, state income taxes, and the classification of each distribution ... What a $2 Million Dividend Portfolio Actually Pays After Taxes in California

Stryker Corporation (NYSE:SYK) was among the stocks on Jim Cramer’s radar on Mad Money, as he advised investors to care about where a stock is going, not where it has been. Toward the end of the lightning round, a caller asked if the stock is a buy, sell, or hold. In response, Cramer said: See, […]

Johnson & Johnson’s model fair value sits at US$252.87 per share, with analysts keeping price targets anchored to that unchanged estimate. Recent research links those steady targets to a mix of optimism around Icotyde, Inlexzo and the broader drug pipeline, balanced against policy questions and partnership headwinds that could influence how investors think about execution risk. As you read on, you will see how these moving pieces shape the evolving Johnson & Johnson story and what to watch...

A $1 million portfolio is often discussed as though the balance itself answers the retirement question. It does not. What matters is the amount of income that ultimately reaches your bank account after taxes. The yield displayed on a brokerage statement is only the starting point. Federal taxes, state taxes, and the type of income ... The $1 Million Retirement Mistake: Counting Income You’ll Never Get to Spend

Ten thousand dollars a month works out to $120,000 a year, an income stream that exceeds the roughly $68,359 in per-capita disposable personal income reported by the Bureau of Economic Analysis for the first quarter of 2026. For many retirees, that level of cash flow would support a lifestyle well above basic needs. The real ... The Retirement Portfolio That Forks Over a $10,000 Check Every Month

I'm not buying into SpaceX following the record-setting IPO. But I am looking for big value elsewhere. Here's how I start my search.

Bear markets are a part of investing life, but you can prepare for them ahead of time.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

The stock market isn’t going to fall again, at least in this century. The S&P is up 8% this year. It is up 25% in the last year, and 80% over the last five. Some stocks of relatively well-known companies have doubled or better since January 1. Among the most extraordinary is the dying chip ... If You Think The Market Will Ever Fall, Buy This

J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.

Johnson & Johnson (NYSE:JNJ) is included among the Dividend Stock Portfolio: Top 10 Stocks to Buy According to Reddit. On May 31, Reuters reported that Johnson & Johnson (NYSE:JNJ)’s prostate cancer drug Erleada, when used alongside hormone-blocking therapy for six months before and after prostate surgery, improved the chances of eliminating cancer and lowered the […]

Johnson & Johnson (JNJ) reached $228.39 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.

Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Broadcom Inc. (AVGO) and Johnson & Johnson (JNJ), as well as two micro-cap stocks, Franklin Wireless Corp. (FKWL) and Park Aerospace Corp. (PKE).

The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.

A $2 million investment portfolio can generate a six-figure income stream without tenants, maintenance calls, property tax surprises, or vacancy risk. The arithmetic is straightforward. The challenge is deciding how much yield to pursue and understanding the trade-offs that come with it. To make a fair comparison, start with rental real estate. Many landlords aim ... This $2 Million Portfolio Pays a Six-Figure Income Without Owning a Single Rental Property

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

The Dividend Kings include more than 50 stocks with steadily rising payouts. They’re hard to beat for dividend safety.

With a net profit margin of 21.83%, Johnson & Johnson (NYSE:JNJ) is included among the 12 Most Profitable American Stocks to Buy in 2026. Johnson & Johnson (NYSE:JNJ) and its subsidiaries develop, manufacture, and sell a broad range of healthcare products, giving the company a presence across multiple areas of the healthcare industry. The company’s dividend […]

Johnson & Johnson (NYSE:JNJ) reported Phase 3 results for TALVEY plus DARZALEX FASPRO in relapsed or refractory multiple myeloma, showing improved outcomes versus standard regimens. The MonumenTAL-3 study is the first to show a GPRC5D bispecific antibody combination achieving these results in earlier treatment lines. Findings were published in The New England Journal of Medicine and presented at a major scientific meeting, highlighting clinical and commercial relevance. Johnson & Johnson...

US stocks (^DJI, ^IXIC, ^GSPC) ended Wednesday's session in negative territory after Federal Reserve officials unanimously voted to hold interest rates at their June FOMC meeting today, while also forecasting at least one possible rate hike ahead. Yahoo Finance Markets and Data Editor Jared Blikre breaks down the trading day's market reactions to the Fed's big decision. This was Kevin Warsh's first FOMC meeting he presided over as the new chairman of the Fed.

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.